Article Figures & Data
Figures
- 1
Kaplan-Meier curves showing cumulative recurrence-free survival of HCC patients who underwent curative resection categorized according to-402GG, GA and AA (left) or -402GG and non-GG (right) genotypes in the FVII promoter region. HCC patients (n=37) were followed up after tumor resection. P value was calculated using a log-rank test.
- 2
Cumulative overall survival of patients with resected HCC categorized according to -402GG, GA and AA (left) or -402GG and non-GG (right) genotypes in the FVII promoter region. HCC patients (n=37) were followed up for the analysis. P value was calculated using a log-rank test.
Tables
Iterm Value Patient demographics Age (years) (median; range) 55 (37–75) Sex (male : female) 29: 8 AFP (ng/mL) (median; range) 24.9 (1.99–303145) Multiple tumor (+) (%) 9 (24.32%) Tumor size (cm) (median; range)a 3.5 (1–19.3) Liver cirrhosis (+) (%) 18 (48.65%) Hepatitis (B : C : B+C : none) 23: 6: 0: 8 TNM stage (I : II : III)b 7: 19: 9 Hypertension (+) (%) 9 (24.3%) Diabetes mellitus (+) (%) 9 (24.3%) Ischemic heart disease (+) (%) 0 (0%) Pathological features Capsule (yes : no) 6: 28 Satellite nodule (yes : no) 5: 30 Microvascular invasion (yes : no) 25: 10 Histological grade (I : II : III) 5: 27: 1 a Measured by the diameter of the largest tumor nodule. b TNM stage classification according to AJCC staging 7th Edition.
Variable HCC (n=37) Donors (n=30) P Age (years) (median; range) 55 (37–75) 29 (20–54) <.0001* Sex (male : female) 29:8 15:15 0.030* INR (mean±SD) 1.03±0.06 1.04±0.08 0.759 Hemoglobin (g/dL) (mean±SD) 13.82±1.95 13.01±1.53 0.067 Hematocrit (%) (mean±SD) 41.35±5.47 39.3±4.13 0.093 Platelet (1000/μL) (mean±SD) 190.14±84.33* 259.47±62.82 <0.001* Hypertension (+) (%) 0 9 (24.3%) - Diabetes mellitus (+) (%) 0 9 (24.3%) - Ischemic heart disease (+) (%) 0 0 - Significant differences (*) were compared to donor group as control. INR: international normalized ratio.
- 3
Distribution of three common polymorphisms, –401 G/T, –323 ins 10-bp, and –122 T/C of FVII gene in HCC patients and healthy donors
FVII polymorphism Donors (n=5) HCC (n=16) P –401G/T 0.597 GG 5 (100%) 15 (93.75%) GT 0 (0%) 1 (6.25%) TT 0 (0%) 0 (0%) G allele 100% 96.88% T allele 0% 3.13% –323ins10-bp 0.597 w/w 5 (100%) 15 (93.75%) ins/w 0 (0%) 1 (6.25%) ins/ins 0 (0%) 0 (0%) w allele 100% 96.88% ins allele 0% 3.13% –122T/C 0.597 TT 5 (100%) 15 (93.75%) TC 0 (0%) 1 (6.25%) CC 0 (0%) 0 (0%) T allele 100% 96.88% C allele 0% 3.13% FVII polymorphism Donors (n=30) HCC (n=37) P –402G/A GG 7 (23.3%) 14 (37.8%) 0.291 GA 16 (53.4%) 13 (35.2%) AA 7 (23.3%) 10 (27%) G allele 50% 55.41% T allele 50% 44.59% GG 7 (23.3%) 14 (37.9%) 0.312 Non-GG 23 (76.7) 23 (62.2%) - 5
Comparison of pathological features between SNP-positive and -negative at –402 of FVII promoter in HCC patients
Variable –402 SNP type P Total GG Non-GG Age (years) 1.000 ≥ 50 25 9 16 < 50 12 5 7 Sex 0.700 Male 29 11 18 Female 8 3 5 AFP (ng/mL) 0.840 < 20 18 7 11 ≥ 20 19 7 12 Tumor size (cm) 0.120 ≥ 5 cm 14 8 6 < 5 cm 23 6 17 Liver cirrhosis 0.640 Present 18 8 10 Absent 19 6 13 Hepatitis 0.930 B 23 8 15 C 6 3 3 B+C 0 0 0 NBNC 8 3 5 TNM stage 0.300 I 7 1 6 II 19 9 10 III 9 4 5 Pathological features 1.000 Capsule Present 6 2 4 Absent 28 12 16 Satellite nodule 0.624 Present 5 2 3 Absent 30 12 18 Microvascular invasion 0.699 Present 25 10 15 Absent 10 4 6 Histological grade 0.345 I 5 1 4 II 27 13 14 III 1 0 1 SNP; single nucleotide polymorphism.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.